Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628362 | 1.00 | SSTR4 (0.31) | SSTR4 | |
| SCHEMBL29847388 | 0.83 | KDM4E (0.32) | — | |
| SCHEMBL8775679 | 0.81 | CYP3A4 (0.36) | SSTR4 | |
| SCHEMBL23175102 | 0.77 | — | — | |
| SCHEMBL19551407 | 0.73 | SSTR4 (0.33) | SSTR4 | |
| SCHEMBL30381859 | 0.69 | SSTR4 (0.33) | SSTR4 | |
| SCHEMBL5035038 | 0.69 | SSTR4 (0.31) | SSTR4 | |
| SCHEMBL1731658 | 0.69 | — | — | |
| SCHEMBL28693636 | 0.67 | KDM4E (0.36) | — | |
| SCHEMBL28931252 | 0.67 | KDM4E (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078188-B2 | Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200031802-A1 | DIHYDROQUINOXALINE BROMODOMAIN RECOGNITION PROTEIN INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031802-A1 | DIHYDROQUINOXALINE BROMODOMAIN RECOGNITION PROTEIN INHIBITOR, PREPARATION METHOD AND USE THEREOF | BRD4, BRPF3, BRD1 | SSTR4 4539/4885 |
| US-11078188-B2 | Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof | BRD4, BRPF3, BRD1 | SSTR4 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.